Last checked at 1 May 2020 10:32
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Grant of Options and PDMR notification
Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, today announces that options to subscribe for an aggregate 546,052 ordinary shares of £0.01 each in the Company ("Ordinary Shares") were granted to Matthew Luttrell, Chief Commercial Officer, Tariq Sethi, Chief Scientific Officer, and Ron Kirschner, General Counsel & Company Secretary as follows:
Name | Position | Number of Share Options Awarded | Exercise Price per Share |
Matthew Luttrell | Chief Commercial Officer | 223,684 | £0.76 |
Tariq Sethi | Chief Scientific Officer | 92,105 | £0.76 |
Ron Kirschner | General Counsel & Company Secretary | 230,263 | £0.76 |
The Options have been granted under the 2016 Share Option Plan and have an exercise price of £0.76, being the closing price of shares at 30 April 2020.
Other than the grant of the Options, none of Mr Luttrell, Mr Sethi or Mr Kirschner or their respective connected persons have any beneficial interest in the Ordinary Shares of the Company.
This announcement, including the notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| 1) Matthew Luttrell 2) Tariq Sethi 3) Ron Kirschner | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| 1) Chief Commercial Officer 2) Chief Scientific Officer 3) General Counsel & Company Secretary | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Oncimmune Holdings plc | |||
b)
| LEI
| 213800HCYIWT6YPI1I02 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each
| |||
Identification code | ISIN: GB00BYQ94H38 | ||||
b)
| Nature of the transaction
| Grant of options | |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
1) £0.76 | 223,684 | ||||
2) £0.76 | 92,105 | ||||
3) £0.76 | 230,263 | ||||
d)
| Aggregated information | ||||
- Aggregated volume | 546,052 | ||||
- Price | £414,999.52 | ||||
e)
| Date of the transaction
| 1 May 2020 | |||
f)
| Place of the transaction
| Outside a trading venue | |||
For further information:
Oncimmune Holdings plc
Ron Kirschner, General Counsel & Company Secretary
contact@oncimmune.co.uk